Evaluation of human recession defects treated with coronally advanced flaps and either purified recombinant human platelet-derived growth factor-BB with beta tricalcium phosphate or connective tissue: a histologic and microcomputed tomographic examination.
The current study examined the histologic and microcomputed tomographic (micro CT) outcomes of the treatment of gingival recession defects with either a subepithelial connective tissue graft (CTG) or 0.3 mg/mL recombinant human platelet-derived growth factor (rhPDGF-BB) on a beta tricalcium phosphate (beta-TCP) matrix. Gingival recession defects were surgically created in six premolar teeth with no more than 3 mm of keratinized marginal tissue, an osseous crest 2 to 3 mm apical to the newly created gingival margin, and recession depth of at least 3 mm. The defects were left untouched for 2 months; then, four defects were grafted with rhPDGF-BB + beta-TCP + a wound healing dressing, and two defects received CTGs. A coronally advanced flap covered each grafted site. Nine months later, sections were obtained for examination. All four sites treated with rhPDGF-BB + beta-TCP showed connective tissue fibers (Sharpey fibers) perpendicularly inserting into newly formed cementum and alveolar bone. In the two sites treated with CTGs, a long junctional epithelium was seen coronal to the osseous crest and connective tissue fibers ran parallel to the adjacent root surfaces, with no evidence of insertion into cementum or bone. There was no evidence of regeneration of cementum, inserting connective tissue fibers, or supporting alveolar bone. Regeneration of the periodontium in gingival recession defects is possible through growth factor-mediated therapy.
McGuire
Michael K
MK
mkmperio@swbell.net
Scheyer
Todd
T
Nevins
Myron
M
Schupbach
Peter
P
D000539:Alveolar Process / Q000000981:diagnostic imaging; D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage*; D000077214:Becaplermin; D001861:Bone Regeneration; D002130:Calcium Phosphates; D003094:Collagen; D003238:Connective Tissue / Q000637:transplantation*; D003739:Dental Cementum / Q000502:physiology; D004337:Drug Carriers; D005500:Follow-Up Studies; D005889:Gingival Recession / Q000601:surgery*; D006801:Humans; D010513:Periodontal Ligament / Q000502:physiology; D010982:Platelet-Derived Growth Factor / Q000008:administration & dosage*; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins / Q000008:administration & dosage; D012038:Regeneration / Q000187:drug effects*; D016896:Treatment Outcome; D055114:X-Ray Microtomography
D043925:Angiogenesis Inducing Agents; D002130:Calcium Phosphates; D004337:Drug Carriers; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; C485817:beta-tricalcium phosphate; D000077214:Becaplermin; D003094:Collagen